WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Laci M. Adolfo
Patent Agent
Patents and Innovations
Boulder
ladolfo@wsgr.com

D303-256-5911

Download vCard
Open PDF

Dr. Laci M. Adolfo is a patent agent in the Boulder office of Wilson Sonsini Goodrich & Rosati, where she assists with patent prosecution and intellectual property matters serving clients in a wide range of technology fields, including pharmaceutical and biotechnology industries.

Prior to joining the firm, Laci worked as a research and development scientist to develop protocols for next-generation sequencing. During her doctoral studies in the laboratory of Dr. Richard A. Dixon, Laci researched secondary metabolite biosynthesis in a non-model plant and developed an agrobacterium-mediated cell culture technique.

Experience

Dr. Laci M. Adolfo is a patent agent in the Boulder office of Wilson Sonsini Goodrich & Rosati, where she assists with patent prosecution and intellectual property matters serving clients in a wide range of technology fields, including pharmaceutical and biotechnology industries.

Prior to joining the firm, Laci worked as a research and development scientist to develop protocols for next-generation sequencing. During her doctoral studies in the laboratory of Dr. Richard A. Dixon, Laci researched secondary metabolite biosynthesis in a non-model plant and developed an agrobacterium-mediated cell culture technique.

Education
  • Ph.D., Biochemistry and Molecular Biology, University of North Texas
  • B.S., Biological Sciences, University of North Texas
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Ph.D., Biochemistry and Molecular Biology, University of North Texas
  • B.S., Biological Sciences, University of North Texas
Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author with D. Burks, X. Rao, A. Alvarez-Hernandez, and R.A. Dixon, “Evaluation of pathways to the C-glycosyl isoflavone puerarin in roots of kudzu (Pueraria montana lobata),” 6(9) Plant Direct, 2022
  • Co-author with X. Rao and R.A. Dixon, “Identification of Pueraria spp. through DNA barcoding and comparative transcriptomics,” 22(10) BMC Plant Biology, 2022
Insights

Select Publications

  • Co-author with D. Burks, X. Rao, A. Alvarez-Hernandez, and R.A. Dixon, “Evaluation of pathways to the C-glycosyl isoflavone puerarin in roots of kudzu (Pueraria montana lobata),” 6(9) Plant Direct, 2022
  • Co-author with X. Rao and R.A. Dixon, “Identification of Pueraria spp. through DNA barcoding and comparative transcriptomics,” 22(10) BMC Plant Biology, 2022

Biological Sciences and Biotechnology

  • Biochemical assays
  • Biochemistry
  • Cell culture products
  • Genetics
  • Genomics
  • Molecular biology
  • Molecular genetics
  • PCR

Therapeutics and Drug Discovery

  • RNA interference (RNAi)

Diagnostics and Medical Devices

  • Diagnostics

Genomics and Data Analysis

  • Next-generation sequencing
  • Sequencing
Technical Fluency

Biological Sciences and Biotechnology

  • Biochemical assays
  • Biochemistry
  • Cell culture products
  • Genetics
  • Genomics
  • Molecular biology
  • Molecular genetics
  • PCR

Therapeutics and Drug Discovery

  • RNA interference (RNAi)

Diagnostics and Medical Devices

  • Diagnostics

Genomics and Data Analysis

  • Next-generation sequencing
  • Sequencing
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises PrognomiQ on Patent Matters Related to $34 Million Series D
On November 5, 2024, PrognomiQ, a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases, announced the succesful completion of a $34 million Series D financing. The round was led by Seer with participation from Catalio Capital Management, aMoon, Invus, and Bruker. Wilson Sonsini Goodrich & Rosati advised PrognomiQ on patent matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Karius on IP Matters Related to $100 Million Series C
On May 2, 2024, Karius®, Inc. (Karius), a world leader in genomic diagnostics for infectious disease, announced the successful completion of a $100 million Series C financing. Khosla Ventures, along with new investors 5AM Ventures and Gilde Healthcare, co-led the round. New investor Seventure Partners, and existing investors Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Ventures, and others also participated. Wilson Sonsini Goodrich & Rosati advised Karius on IP matters related to the transaction.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.